You can buy or sell MyoKardia and other stocks, options, ETFs, and crypto commission-free!
MyoKardia, Inc. Common Stock, also called MyoKardia, is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Read More Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.
52 Week High
52 Week Low
— per share
Expected Nov 2, After Hours